Home » Drug Information » FDA Approved Drugs » 2000
Medical Areas: Cardiology/Vascular Diseases | Endocrinology | Family Medicine
View By:YearCompanyConditionsTherapeutic AreasDrug Names
Atacand (candesartan cilexetil)
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: AstraZeneca
Approval Status: Approved September 2000
Treatment Area: For the treatment of hypertension
General Information
Atacand HCT (candesartan cilexetil-hydrochlorothiazide) has been
developed for the treatment of hypertension, and may be helpful
when single products are unsuccessful in reducing blood pressure.
Atacand HCT consists of two active ingredients: an angiotensin II
receptor antagonist and a diuretic hydrochlorothiazide. It works by
inhibiting the effects of angiotensin II, which is an agent that
causes vasoconstriction and high blood pressure. Additionally,
hydrochlorothiazide reduces blood pressure by improving the
kidneys' ability to eliminate salt and fluid from the body.
Atacand HCT is available in two tablet strengths: 32 mg
Atacand-12.5 mg hydrochlorothiazide and 16 mg Atacand-12.5 mg
hydrochlorothiazide.
Clinical Results
Five double-blind, placebo-controlled trials evaluated
candesartan cilexetil-hydrochlorothiazide. These five trials, of 8
to 12 weeks duration, consisted of 3037 hypertensive patients.
Doses ranged from 2 to 32 mg candesartan cilexetil and from 6.25 to
25 mg hydrochlorothiazide administered once daily in various
combinations.
The combination of candesartan cilexetil-hydrochlorothiazide
resulted in placebo-adjusted decreases in sitting systolic and
diastolic blood pressures of 14-18/8-11 mm Hg at doses of 16-12.5
mg and 32-12.5 mg (the two tablet stengths). In long-term studies
of up to one year, the blood pressure lowering effect of the
combination was maintained.
Side Effects
The most common adverse events observed with Atacand HCT use
include the following:
- Upper respiratory infection
- Dizziness
- Back pain
- Flu-like symptoms
Atacand HCT should not be used by pregnant women and should be
discontinued if pregnancy is detected.
Mechanism of Action
Angiotensin II is formed from angiotensin I in a reaction
catalyzed by angiotensin-converting enzyme (ACE). Angiotensin II is
the principal pressor agent of the renin-angiotensin system, with
effects that include vasoconstriction, stimulation of synthesis and
release of aldosterone, cardiac stimulation, and renal reabsorption
of sodium. Candesartan blocks the vasoconstrictor and
aldosterone-secreting effects of angiotensin II by selectively
blocking the binding of angiotensin II to the AT1 receptor in many
tissues. Its action is, therefore, independent of the pathways for
angiotensin II synthesis.
Hydrochlorothiazide is a thiazide diuretic. Thiazides affect the
renal tubular mechanisms of electrolyte reabsorption, directly
increasing excretion of sodium and chloride in approximately
equivalent amounts. Indirectly, the diuretic action of
hydrochlorothiazide reduces plasma volume, with consequent
increases in plasma renin activity, increases in aldosterone
secretion, increases in urinary potassium loss, and decreases in
serum potassium. (from FDA Label)
Additional Information
Approximately one in every four American adults, and more than
half of all Americans over age 65 have high blood pressure. For
more information on hypertension and heart-related conditions
please visit the web site of the
American
Heart Association.
For more information on Atacand HCT, please visit the web site
of AstraZeneca.